Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | XmAb20717 |
Trade Name | |
Synonyms | XmAb 20717|Vudalimab |
Drug Descriptions |
XmAb20717 (Vudalimab) is a bispecific antibody that targets both PD-1 (PDCD1) and CTLA4, potentially resulting in increased anti-tumor immune response (Journal for ImmunoTherapy of Cancer 2021;9). |
DrugClasses | CTLA4 Antibody 31 Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 |
CAS Registry Number | 2329669-72-7 |
NCIT ID | C150463 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Abiraterone + Docetaxel + XmAb20717 | Abiraterone Docetaxel XmAb20717 | 0 | 1 |
Abiraterone + XmAb20717 | Abiraterone XmAb20717 | 0 | 1 |
Cabazitaxel + Carboplatin + XmAb20717 | Cabazitaxel Carboplatin XmAb20717 | 0 | 1 |
Carboplatin + Pemetrexed Disodium + XmAb20717 | Carboplatin Pemetrexed Disodium XmAb20717 | 0 | 1 |
Enzalutamide + XmAb20717 | Enzalutamide XmAb20717 | 0 | 1 |
Olaparib + XmAb20717 | Olaparib XmAb20717 | 0 | 1 |
Regorafenib + XmAb20717 | Regorafenib XmAb20717 | 0 | 1 |
XmAb20717 | XmAb20717 | 0 | 6 |